Panel Discussion | Challenges in Clinical Trials Design

Monday, March 9, 2026

9:33 AM - 9:50 AM EST

Location: Spotlight Theater

Moderator(s)

Donald E. Cutlip, MD, FACC

Vice Chair, Department of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

Disclosure(s): Cordis Corporation: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)
Andrew Farb, MD

Chief Medical Officer, Office of Cardiovascular Devices
U.S. Food and Drug Administration
Silver Spring, Maryland, United States

Disclosure information not submitted.

Panel Discussant(s)

Jodi J. Akin, MS

Chairwoman, BOD
CoreMedic
Alamo, California, United States

Disclosure information not submitted.
Andrew D. Althouse, PhD

Senior Principal Statistician
Medtronic

Disclosure(s): Medtronic, Inc.: Employee (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)
Wayne Batchelor, MD, MHS, MBA

President, Medicine Service Line and Schar Chair, Inova Schar Heart and Vascular
Inova Health System
Fairfax, Virginia, United States

Disclosure(s): Abbott Vascular, Edwards, Medtronic, Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing); Johnson and Johnson: Consulting Fees (e.g., advisory boards) (Ongoing); Recor Medical, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing)
Jan Tijssen, PhD

Emeritus Professor of Clinical Biostatistics
Amsterdam University Medical Centers - University of Amsterdam
Naarden, Noord-Holland, Netherlands

Disclosure information not submitted.

Disclosure(s):

Donald E. Cutlip, MD, FACC: Cordis Corporation: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)

Andrew D. Althouse, PhD: Medtronic, Inc.: Employee (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)

Wayne Batchelor, MD, MHS, MBA: Abbott Vascular, Edwards, Medtronic, Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing); Johnson and Johnson: Consulting Fees (e.g., advisory boards) (Ongoing); Recor Medical, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing)